Foster & Motley Inc. Lowers Stock Holdings in Danaher Co. (NYSE:DHR)

Foster & Motley Inc. reduced its position in Danaher Co. (NYSE:DHR) by 6.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 1,582 shares of the conglomerate’s stock after selling 103 shares during the quarter. Foster & Motley Inc.’s holdings in Danaher were worth $366,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Banco Santander S.A. bought a new position in shares of Danaher in the third quarter worth $683,000. First Citizens Bank & Trust Co. grew its position in Danaher by 0.6% during the fourth quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after buying an additional 149 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Danaher by 48.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after acquiring an additional 96,395 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Danaher by 4.8% in the 3rd quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock valued at $764,000 after acquiring an additional 142 shares in the last quarter. Finally, Keybank National Association OH boosted its position in shares of Danaher by 0.5% during the 3rd quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock valued at $137,238,000 after acquiring an additional 2,567 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In related news, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the sale, the senior vice president now owns 4,244 shares in the company, valued at $1,029,891.48. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at $9,601,704. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 2,622 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The disclosure for this sale can be found here. Insiders sold a total of 32,957 shares of company stock worth $8,265,802 over the last quarter. 11.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of recent analyst reports. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and raised their target price for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. TD Cowen lifted their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Raymond James lifted their price target on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Finally, Royal Bank of Canada increased their price objective on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average price target of $270.00.

Danaher Trading Down 1.1 %

Shares of DHR opened at $250.41 on Thursday. The stock has a market capitalization of $185.44 billion, a P/E ratio of 42.44, a PEG ratio of 4.24 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. The firm has a fifty day simple moving average of $249.00 and a two-hundred day simple moving average of $230.78.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.48%. Danaher’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same period in the prior year, the business posted $2.36 earnings per share. On average, research analysts anticipate that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date is Wednesday, March 27th. This is an increase from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio is currently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.